Opinion of the Transparency Council – trabektedine
At its meeting on 26 August 2024, the Transparency Council adopted opinion No. 139/2024 on the transfer of the active substance trabektedine from the drug program: B.8 “Treatment of patients with soft tissue sarcomas (ICD-10: C48, C49)” to the catalog of reimbursable drugs in chemotherapy